Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2008

View Archived Issues

PNU-165442G improves stress urinary incontinence in women in phase II study

Significant bronchoprotection seen with BI-1744-CL in asthma patients

New data on pasireotide activity in bronchial carcinoids, acromegaly presented

Dose-dependent immunogenicity seen with meningococcal group B vaccine candidate rLP-2086

MEK inhibition with RDEA-119 beneficial in colitis model

Responses to romidepsin seen in phase II cutaneous T-cell lymphoma study

Recent Gruenenthal patents report novel analgesic agents

Elaprase approved in Brazil

Alnylam and Takeda form RNAi alliance

Emergent BioSolutions to acquire Protein Sciences' operations

Relistor approved in Canada

New agents for treating HCV infection disclosed a recent Merck patent

MVA-BN HIV multiantigen begins phase I/II study in HIV

Novel treatment options for lipoprotein disorders described in recent patent literature

DiaMedica announces last patient out for phase II DM-83 trial

EpiCept files re-examination documentation for Ceplene MAA

GVK Bio enters into drug discovery collaboration with Wyeth

Lonza acquires cell discovery company Amaxa

PCI Biotech passes planned resolutions for demerger of Photocure

Boehringer Ingelheim invests in new, leading-edge laboratories in Canada

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...